Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $27.43 Consensus Price Target from Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $27.4286.

Several equities research analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday. Weiss Ratings downgraded shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Jefferies Financial Group reissued a “hold” rating and set a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Barclays reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 8th. Finally, Wells Fargo & Company reduced their target price on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, February 27th.

Trending Headlines about Amphastar Pharmaceuticals

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Negative Sentiment: Amphastar reported adjusted earnings of $0.42 per share on revenue of $171.2 million, missing analyst estimates of about $0.70 EPS and $173.5 million in sales, which is the main reason the stock is moving lower. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
• Negative Sentiment: The company’s GAAP net income was $6.4 million, or $0.14 per share, highlighting weaker bottom-line performance than the adjusted figures suggest. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
• Neutral Sentiment: Needham & Company reaffirmed its hold rating, suggesting analysts are cautious but not turning more bearish after the results.
• Neutral Sentiment: Management also said BAQSIMI revenue is expected to be flat to up low-single-digits, with a 3% list price increase, offering some stability in a key product line. Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AMPH. Farther Finance Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 356.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock valued at $25,000 after acquiring an additional 737 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Global Retirement Partners LLC grew its position in shares of Amphastar Pharmaceuticals by 219.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after acquiring an additional 703 shares during the period. Quarry LP bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $32,000. Finally, GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after buying an additional 462 shares during the period. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Trading Down 20.9%

NASDAQ:AMPH opened at $19.00 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.90 and a current ratio of 4.02. The firm has a market cap of $846.07 million, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 1.54 and a beta of 0.97. Amphastar Pharmaceuticals has a 52 week low of $17.03 and a 52 week high of $31.26. The firm has a 50-day moving average price of $20.80 and a two-hundred day moving average price of $24.57.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.28). The firm had revenue of $171.17 million during the quarter, compared to analysts’ expectations of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.11%. On average, equities analysts expect that Amphastar Pharmaceuticals will post 2.93 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.